Pfizer Inc. delivered the news the world was waiting for on 9 November, announcing its vaccine for COVID-19, developed with BioNTech SE, had a 90% efficacy rate in an interim analysis of an ongoing Phase III trial. The next step is waiting for the safety data, which could come next week and will inform a decision about regulatory filing.
At 90%, the initial efficacy rate is much higher than the 50% threshold the US Food and Drug Administration has...







